UBS Group
PKBOW

UBS Group’s Peak Bio, Inc. Warrant PKBOW Stock Holding History

UBS Group’s Portfolio PKBOW Stock Details PKBOW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed – – 11565
2022
Q3 		$0 Hold
100
– – ﹤0.01% 11499
2022
Q2 		$0 Buy
+100
New +$32 ﹤0.01% 11476
2021
Q3 		– Sell
-90
Closed – – 10437
2021
Q2 		$0 Hold
90
– – ﹤0.01% 10092
2021
Q1 		$0 Buy
+90
New +$101 ﹤0.01% 9707

Other funds holding PKBOW

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

UBS Group's PKBOW Position: Q4 2022 in Review

UBS Group sold out of Peak Bio, Inc. Warrant (PKBOW) in Q4 2022, closing a stake of 100 shares.

UBS Group first reported a position in PKBOW in Q1 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 15 funds tracked by Wall St. Rank hold PKBOW as of Q4 2022.

  • UBS Group reported no remaining Peak Bio, Inc. Warrant position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 100 Peak Bio, Inc. Warrant shares in Q4 2022.
  • UBS Group first reported a position in Peak Bio, Inc. Warrant in Q1 2021 and held it in 4 quarters.
  • UBS Group's Peak Bio, Inc. Warrant position peaked at $0 in Q3 2022.
  • 15 funds tracked by Wall St. Rank held Peak Bio, Inc. Warrant as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.